• All
  • Accelerator I / II
  • Accelerator III

Through a combination of generous seed funding, access to management and scientific experts, state-of-the-art laboratory facilities and collaborative office space, Accelerator provides start-ups with a structured toolkit for development, milestone achievement and eventual autonomy. Take a look at a few of the success stories from our growing portfolio of diverse companies

Swipe left or right on the table to view in more detail

Logo Company Source Technology Series A Investment Date Graduation Date Follow On $
Oncofactor Entrepreneur

Oncology: Novel immunotherapy approach and targets for mAbs

$5.3M Q2 2011
Acylin Therapeutics Johns Hopkins, Wistar Institute

Oncology, Metabolic, CNS: Small molecule inhibitors of histone acetyl transferases (HAT’s)

$4.4M Q4 2010 $5.85M
XORI University of Washington

Antibody platform: Novel method for rapidly developing high affinity mAbs

$4.4M Q2 2009 Q3 2011 SOLD
Groove Biopharma Nanogen, Inc.

Oncology, Hematopoeitic Disorders: microRNA inhibition platform solving distribution and delivery

$3.5M Q3 2008 Q4 2011 $9.9M
PharmSelex California Institute of Tech.

Small molecule GPCR Inhibitors: Next generation in-silico drug design platform

$4.5M Q2 2008 N/A N/A
Recodagen Washington State Univ.

Oncology: Novel target to prevent tumor invasion and metastasis

$1.5M Q1 2008 N/A N/A
Seredigm University of Washington

Ischemia/Reperfusion: Recombinant protein effective in-vivo at rescuing I/R injury.

$4.5M Q2 2006 N/A $2.0M
Allozyne California Institute of Tech.

Multiple Indications: Platform for specific improvement of recombinant proteins and mAbs

$3.4M Q4 2005 Q4 2007 $39.0M
Integrated Diagnostics Institute for Systems Biology

Clinical Diagnostics: Biomarker platform for discovery of blood circulating biomarkers indicative of organ disease

$5.0M Q3 2005 Q3 2009 $30.4M
Theraclone Sciences Entrepreneur

Oncology, Infectious Disease: Platform for the discovery of novel mAbs against cancers and pathogens

$2.0M Q4 2004 Q2 2007 $33.4M
VLST Entrepreneur

Autoimmunity/Inflammation: Platform for discovery of new autoimmune and inflammatory targets.

$4.8M Q2 2004 Q2 2006 $45.1M
VieVax Iowa State University

Infectious Disease: Platform for development of vaccines against many pathogens

$1.6M Q1 2004 N/A N/A
  • All
  • Accelerator I / II
  • Accelerator III

Through a combination of generous seed funding, access to management and scientific experts, state-of-the-art laboratory facilities and collaborative office space, Accelerator provides start-ups with a structured toolkit for development, milestone achievement and eventual autonomy. Take a look at a few of the success stories from our growing portfolio of diverse companies

Swipe left or right on the table to view in more detail

Coming Soon.